Bakırtaş, M. Et Al. 2023. Real-world data on the effectiveness and safety of Ixazomib-Lenalidomide-Dexamethasone therapy in relapsed/refractory multiple myeloma patients: a multicenter experience in Turkey. Journal of Chemotherapy , vol.35, no.6 , 563-569.

Bakırtaş, M., Dal, M. S., Yiğenoğlu, T. N., Giden, A. O., Serin, I., Başcı, S., ... Kalpakci, Y.(2023). Real-world data on the effectiveness and safety of Ixazomib-Lenalidomide-Dexamethasone therapy in relapsed/refractory multiple myeloma patients: a multicenter experience in Turkey. Journal of Chemotherapy , vol.35, no.6, 563-569.

Bakırtaş, Mehmet Et Al. "Real-world data on the effectiveness and safety of Ixazomib-Lenalidomide-Dexamethasone therapy in relapsed/refractory multiple myeloma patients: a multicenter experience in Turkey," Journal of Chemotherapy , vol.35, no.6, 563-569, 2023

Bakırtaş, Mehmet Et Al. "Real-world data on the effectiveness and safety of Ixazomib-Lenalidomide-Dexamethasone therapy in relapsed/refractory multiple myeloma patients: a multicenter experience in Turkey." Journal of Chemotherapy , vol.35, no.6, pp.563-569, 2023

Bakırtaş, M. Et Al. (2023) . "Real-world data on the effectiveness and safety of Ixazomib-Lenalidomide-Dexamethasone therapy in relapsed/refractory multiple myeloma patients: a multicenter experience in Turkey." Journal of Chemotherapy , vol.35, no.6, pp.563-569.

@article{article, author={Mehmet Bakırtaş Et Al. }, title={Real-world data on the effectiveness and safety of Ixazomib-Lenalidomide-Dexamethasone therapy in relapsed/refractory multiple myeloma patients: a multicenter experience in Turkey}, journal={Journal of Chemotherapy}, year=2023, pages={563-569} }